C4 Therapeutics Rings the Nasdaq Stock Market Closing Bell
C4 Therapeutics (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, visits the Nasdaq MarketSite in Times Square. In honor of the occasion, Andrew Hirsch, President and Chief Executive Officer of C4 Therapeutics, rings the Closing Bell.